Posted by Michael Wonder on 16 Nov 2024
Different models, same results: considerations when choosing between approaches to model cost effectiveness of chimeric antigen receptor T-cell therapy versus standard of care
7 September 2024 - Chimeric antigen-receptor T-cell therapy (CAR-T) is characterised by early phase data at the time of registration, high upfront cost and a complex manufacturing and administration process compared with standard therapies.
Our objective was to compare the performance of different models to assess the cost effectiveness of CAR-T using a state-transition model, partitioned survival model and discrete event simulation.
